Supplementary Figure S1. Immunoblot analysis of NF1-deficient GBM cells treated with AZD6244. NF1-deficient GBM cells were treated with 500 nM AZD6244 for up to 24 hours, lysed and subjected to SDS-PAGE and immunoblot analysis using the indicated antibodies.

Supplementary Figure S2. Immunoblot and sub-G1 FACs analysis of NF1-deficient GBM cells treated with PD0325901 and/or PI-103. A, NF1-deficient GBM cells were treated with DMSO, 100 nM PD0325901, 500 nM PI-103 or both drugs in combination for 24 hours, lysed and subjected to SDS-PAGE and immunoblot analysis using the indicated antibodies. B, NF1-deficient GBM cells were treated as in A for 5 days and FACS analysis was performed to determine the percentage of cells with sub-G1 (apoptotic) DNA content. Values are the mean of two independent experiments performed in duplicate. Bar, SEM.

Supplementary Figure S3. Immunoblot, cell cycle, and sub-G1 FACs analysis of NF1-proficient GBM cells treated with PD0325901 and/or PI-103. A, NF1-proficient GBM cells were treated with DMSO, 100 nM PD0325901, 500 nM PI-103 or both drugs in combination for 24 hours, lysed and subjected to SDS-PAGE and immunoblot analysis using the indicated antibodies. B, NF1-proficient GBM cells were treated as in A for 5 days and cell growth was determined by counting viable cells. Values are the mean from two independent experiments. Bar, SEM. C, NF1-proficient GBM cells were treated as in A for 5 days and FACS analysis was performed to determine the percentage of
cells with sub-G1 (apoptotic) DNA content. Values are the mean of two independent experiments performed in duplicate. Bar, SEM.